Clinical trial
D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With…
NCT00083876 · University of Arkansas, Other · Completed
Key facts
| NCT number | NCT00083876 |
|---|---|
| Title | D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma |
| Official title | UARK 98-035, A Phase III Study of D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma |
| Lead sponsor | University of Arkansas, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Thalidomide |
| Enrollment | 500 |
| Start date | Sep 1, 1998 |
| Completion | Nov 1, 2007 |
| First posted | Jun 4, 2004 |
| Last update posted | Jul 2, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: